Interleukin-2 treatment of tumor patients can expand regulatory T cells

Figures & data

Figure 1. Interleukin 2 administration results in a preferential expansion of regulatory T (T_reg) cells. Administration of interleukin-2 to tumor patients only results in a weak activation and expansion of potentially tumor-counteracting effector T cells, while memory T_reg cells in the periphery as well as the naïve thymic T_reg-cell pool are consistently expanded.